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EARLY DETECTION of tumour metastasis
is important for the clinical oncologist,
since the therapeutic modalities may be
influenced by the tumour stage. For some
common tumours the first metastases are
often in bone.
The symptoms of skeletal metastasis
either appear late or lack specificity.
Various biochemical markers have been
put forward for the early detection of
tumours or their metastases (Coombes
et al., 1977). For skeletal metastases, the
isoenzymes of alkaline phosphatase were
introduced into the clinical laboratory, but
they did not bring the expected diagnostic
advantage (Fishman & Ghosh, 1967).
The collagen metabolite hydroxyproline
is released mostly from bone but also from
other connective tissue in adults (Laitinen,
1974). It has raised "particular hope and
interest" as a marker of skeletal involve-
ment by tumours (Reynoso, 1973). This
amino acid is fairly specific for bone
turnover. It is produced by hydroxylation
of proline, previously integrated in the
procollagen molecule (Grant & Prockop,
1972) and it is released from bone when
the connective tissue is broken down in
bone turnover (Klein et al., 1964).
Several clinical studies have proved the
relevance of total urinary hydroxyproline
in the diagnosis of various disorders of
bone (for review see Laitinen, 1974) and
particularly in the diagnosis of skeletal
metastasis of various tumours (Basu et al.,
1974; Bonadonna et al., 1966; Guzzo et al.,
1969; Hosley et al., 1966). Kontturi et al.
(1974) have studied free serum hydroxy-
proline (FSHP) in prostatic carcinoma.
Powles et al. (1975) have shown the value
of the total urinary hydroxyproline/
creatinine ratio (HP/CR) for the evalua-
tion of the response to a given treatment
in breast cancer metastatic to the skeleton.
We have planned the present study to
answer to the following questions:
-What is the diagnostic value of FSHP
and HP/CR for the detection of skeletal
metastasis of breast cancer? We were
aware, however, of the relatively low
expected incidence of skeletal metastasis
in such a prospective trial.
-How long is the interval between an
increase of FSHP and HP/CR and the
radiological confirmation of skeletal
involvement?
-Have FSHP and HP/CR an advantage
over alkaline phosphatase?
-Do other types of metastasis influence
FSHP or HP/CR?
The patients under study had been
receiving adjuvant chemotherapy after
mastectomy for breast cancer (patho-
logical stage Tl-3aN+Mo). The treatment
was given in a cooperative trial of the
Swiss group for clinical cancer research
(SAKK 27/76).
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The patients were entered into the study
within 4 weeks after mastectomy. If
postoperative radiotherapywasperformed,
the interval admitted was less than 16
weeks. After initial examination the
patients were randomized between a
treatment for 6 months and a treatment
for 24 months. Chemotherapy consisted
for all patients of oral chlorambucil,
methotrexate and 5-fluorouracil. The
patients were monitored at least every
3 months with clinical, laboratory and
radiological examinations.
The study ended if there was a mor-
phological proof of local recurrence and/or
metastasis, either (whenever possible) by
histology or cytology, or by unequivocal
radiological findings. In respect of skeletal
metastasis a pathological bone scan in the
absence of a clearcut radiological change
was considered insufficient reason for
withdrawing the patient from the study.
The collection of samples for hydroxy-
proline started in the spring of 1976 and
ended in December 1979. The patients
continued to be followed as previously.
We have divided the patients into 5
groups:
I: With no local or distant recurrence
until 1 year after the last hydroxyproline
sample.
II: The same criteria as Group I, but
the patients received no chemotherapy,
since they were taken from a parallel study
with similar criteria but with a control
arm (OSAKO study).
III: With skeletal metastasis.
IV: With liver metastasis.
V: With local recurrence or with
metastasis elsewhere than liver or bone.
For the determination of FSHP and
HP/CR, serum and urine were taken
after an overnight fast and a diet exclud-
ing all collagen for 24 h. Blood was
separated immediately and the serum was
frozen. The chemical methods are detailed
elsewhere (Gasser et al., 1979).
Urinary total HP was measured and
expressed as its ratio to creatinine (CR)
(mM x 100/mM). The normal values for our
laboratory are 0-69-3 05 for HP/CR and
5*2-13*4 pM for FSHP. They have been
calculated as the mean + 2 s.d. of normal
volunteers studied under the same dietary
conditions.
Alkaline phosphatase was measured by
the local laboratories of the group. These
have given their results with different
reference values. For the comparative
analysis we calculated for each value a
relative number of according to the
formula
where A is the actual measured value,
and p. and a are obtained from the local
reference values (L=-mean and or=s.d.).
"Normal" values for ac lie between + 2
and -2.
In order to test the predictive value of
the above measurements, we arranged the
individual results according to the appear-
ance of recurrence at 3 monthly intervals.
For the control groups (I and II), we have
arbitrarily chosen a point of zero time, for
which there is a minimal further follow-up
of 1 year with no sign of recurrence. We
have excluded patients without at least
3 consecutive values during the observa-
tion period.
A classical analysisofvariance (Snedecor
& Cochran, 1967) and a nonparametric
analysis (Urquhart et al., 1973) were
performed. Finally, the 4 following com-
parisons were calculated according to
Kruskal (1952):
Group III vs all other groups for FSHP
and HP/CR and Groups III and IV vs all
other groups for alkaline phosphatase;
-Group V vs Groups I and II;
-Group I vs Group II;
-Group III vs Group IV.
We have considered the results of 127
patients out of the 389 patients entered
into the therapeutic trial. The others had
to be excluded for having inadequate
samples or none. Eighty-six patients had
no recurrence, whilst 9 presented with
skeletal metastasis and 5 with liver meta-
stasis. Other types of recurrence were
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TABLE. Characteristics of the patients: numbers, mean age and menopausal status.
% Premenopausal
Total (O,) Mean age + s.d. (in each group)
All patients 127 (100) 50-3+8-4 52
Without metastasis
Group I
-Group II
WNith skeletal metastasis
(Group III)
W;ith liver metastasis
(Group IV)
With other type of recurrence
(Group V)
found in 27 patients during the observa-
tion period. Ages and details of meno-
pausal status are presented in the Table.
The Figure shows the results for FSHP
(a), for HP/CR (b) and for alkaline phos-
phatase (c). The mean values ( ± s.d.) of
FSHP and of HP/CR of the Groups I and
II are 6 61 + 2 52 pM and 2-79+ 1-00
respectively for 0-3 months before the
end of the study.
There is only one significant difference
for FSHP: between Groups I and II at
0-3 months (P=0.018). For HP/CR there
are 2 significant differences at 0-3 months:
between Groups III and IV (P = 0.007)
and between III and all the other patients
(P < 0-001). This latter difference exists
also at 6-9 months (P=0 01). Another
highly significant difference exists for
alkaline phosphatase at 0-3 months,
between Groups III and IV (with skeletal
and hepatic metastases) and all the other
groups (P= 0 001).
The present prospective study of 2 col-
lagen metabolites (FSHP and HP/CR)
was designed for testing their value for the
detection of bone metastasis. Repeated
determinations of FSHP and HP/CR in a
strictly controlled group of patients under
known conditions had been planned.
Even for many patients over a long
observation period we would expect few
skeletal metastases. For this reason and
the varying numbers of results for every
observation period due to lack of samples,
our results might easily miss a significant
difference.
FSHP did not help us to discover skele-
tal metastasis; under our conditions it was
77 (6;1) 51 - 4 + 9 - 4
9 (7) 50 0+11-3
9 (7) 49-6+ 13-0
5 (4) 49-0+ 10-8
27 (21) 49 9 + 11 0
52t
56
44
40
56
very insensitive. This result disagrees
with that of Kontturi et al. (1974) for
prostatic cancer. Those authors found a
higher sensitivity ofFSHP than ofHP/CR
in their patients with proven or suspected
skeletal involvement. Our previous work
(Gasser et al., 1981) also failed to confirm
theirresults. Thereare manyfalse-negative
results in metastatic bone disease from
various primary tumours (Gasser et al.,
1979). In our present study, there was
only one value outside the normal range.
HP/CR has been shown to be useful in
evaluating the response of malignant
disease with bone involvement to treat-
ment (Powles et al., 1975). Its sensitivity
has been estimated at between 720%
(Coombes et al., 1977) and 92-4% (Bona-
donna et al., 1966).
If we compare the pooled values of
HP/CR for the groups without metastasis
with the reference values ofourlaboratory,
the former are clearly higher. We have
no explanation for this difference. Our
reference values are concordant with those
of others, and there are no differences for
sex or age between 25 and 70 years
(Laitinen, 1974). A relationship to breast
cancer or the surgical procedure seems
highly improbable. Dietary intake of
collagen barely influences the measure-
ment of HP/CR (Gasser et al., 1979;
Posma et al., 1981). We have no evidence
of one of the known conditions which
increase HP/CR. In a recent publication,
Posma et al. (1981) did not find this
increase, but the intraindividual coefficient
ofvariation is up to 7500 in their patients,
though they apparently repeated the
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analysis ofsamples withborderline results.
The patients with skeletal metastasis
have a significantly higher HP/CR than
all the other patients at 0-3 months and
at 6-9 months. If we still doubt the
practical value of these results, it is
because the mean values of these groups
are still within the range of the patients
without metastasis. Only 2/6 patients
with skeletal involvement have clearly
increased values of HP/CR at 0-3
months and there is an almost equal
proportion of increased values in the
other groups. Our data may be relevant
13b X : :-
II
....1li..
£
a
.7
6
5
4
3
.2
I
- in grwp.-
e
25 ..6 37 .
.7. 7 .J 9
.3 4. 3 4
*1 1 2 t ;
10 10' 12 .. 2-
(a)
INt1Xik1'
O ,' I i
te N
. " it
. III
i..I
,V
a, 46
I
7-
o 3
a
.1
9 . I
*349 2 6... ( 9
56 6-- 8
6 7 .8.
4 5
11 22 22
i
.(b)
.. W ...
A 4 ..
.. 5.
6
2
-2
-2i
I. 111
JU-i ..
W
y
t1.41 11111' "f'r
*p 45
I
o 5
a I
A 16 I
,
{
942 4 4
53 S4 s
3 2 1
6. 6 J
2 5
15 23 22;
(c)
I1 L II
_4
63
3
l.. .s.u
.. .:: *:S
FIGURE.-Mean values +s.d. of the study
parameters from 12-15 months to 0-3
months before the end of the study. Num-
ber per group indicates the number of
individual values. Group I-V refers to the
type of metastasis: Group I and II no
metastasis, Group III skeletal metastasis,
Group IV liver metastasis, Group V with
local recurrence or other type ofmetastasis.
All groups except II were treated with
adjuvant chemotherapy. (a) Free serum
hydroxyproline (FSHP, FM). (b) Urinary
hydroxyproline/creatinine ratio (HP/CR)
in an early morning sample. (c) Alkaline
phosphatase, in relative units ( x ) (for
details seetext).
enough to confirm thesuggestion ofGielen
13 -- et al. (1976) that HP/CR had little
diagnostic value for bone metastasis when
there are no clinical symptoms.
Alkaline phosphatase is correlated with
the totalurinaryHPexcretion (Courvoisier
& Zender, 1972; Klein et al., 1964). It is
a standard biochemical test for the detec-
tion of skeletal metastasis, though its
limitations are well known. In comparison
with FSHP and HP/CR, it seems more *1 sensitive at 0-3 months, for it rises clearly
above normal levels when skeletal and
liver metastases are concerned. Obviously
it cannot separate Groups III and IV,
whereas HP/CR distinguishes them sig-
0$3eflt nificantly.
In conclusion, therefore, we have pros-
8 pectively studied patients operated for
6 v breast cancer and treated by adjuvant
21 chemotherapy of variable duration. We
were interested in the diagnostic value of
.
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FSHP and HP/CR for the detection of
skeletal metastasis, in comparison with
alkaline phosphatase. Few of the patients
presented with bone involvement proven
by radiology, and neither FSHP and
HP/CR proved of predictive value in this
setting. Alkaline phosphatase increased
significantly in patients with bone and
liver metastases 0-3 months before they
were confirmed. HP/CR distinguished the
2 groups significantly. Neither the sensi-
tivity nor the specificity of alkaline
phosphatase are better than those of
HP/CR.
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